The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 26, 2016

Filed:

Jun. 22, 2011
Applicants:

Steven W. Dow, Littleton, CO (US);

Angela J Henderson, Fort Collins, CO (US);

Leah Mitchell, Fort Collins, CO (US);

Inventors:

Steven W. Dow, Littleton, CO (US);

Angela J Henderson, Fort Collins, CO (US);

Leah Mitchell, Fort Collins, CO (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 31/438 (2006.01); A61K 31/4184 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/5386 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 31/438 (2013.01); A61K 31/4184 (2013.01); A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/5386 (2013.01); A61K 39/395 (2013.01);
Abstract

Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.


Find Patent Forward Citations

Loading…